CMAB Biopharma (Suzhou) Inc said on Tuesday that its partner Innovent Biologics Inc (1801.HK) has received US Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) application for its antibody candidate targeting the COVID-19 virus.
Utilizing its state of the art facility and robust quality systems, CMAB has provided integrated CDMO services for Innovent's programme from cell bank construction to cGMP production of drug substance at the 2,000 L upstream scale.
Throughout Innovent's independently-developed project, the two organizations worked together to successfully complete the CMC activities efficiently, rapidly and according to international regulatory standards, added Dr Yongzhong Wang, CEO of CMAB,
CMAB is a flexible full-service CDMO dedicated to providing bespoke development manufacturing services of antibodies and biologics for clients in China and across the globe. CMAB complies with global quality standards with European commission EudraLex (EMA) Vol 4.
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid